How long until I notice cognitive effects?

Mood and gut-related symptoms often shift within 5–14 days. Cognitive recovery and inflammation-related changes accumulate across 4–8 weeks. Stimulant-like 'feel it today' effects are not the typical CJC-1295 with DAC profile; the compound is restorative rather than acutely activating.

Is CJC-1295 with DAC a true nootropic?

Not in the caffeine-or-modafinil sense. CJC-1295 with DAC does not acutely sharpen attention or working memory in healthy users. Its cognitive value is restorative — supporting recovery from neurological injury, reducing chronic neuroinflammation, and stabilising the upstream systems that cognitive function depends on.

Can CJC-1295 with DAC be stacked with other nootropics?

Yes, and it is commonly paired. The cleanest pairings are with compounds on complementary pathways — anxiolytic (selank), neurotrophic (semax), sleep-architecture (DSIP), or anti-inflammatory (LL-37) — rather than with other compounds engaging the same pathway.

How long until I notice cognitive effects?

Mood and gut-related symptoms often shift within 5–14 days. Cognitive recovery and inflammation-related changes accumulate across 4–8 weeks. Stimulant-like 'feel it today' effects are not the typical CJC-1295 with DAC profile; the compound is restorative rather than acutely activating.

Is CJC-1295 with DAC a true nootropic?

Not in the caffeine-or-modafinil sense. CJC-1295 with DAC does not acutely sharpen attention or working memory in healthy users. Its cognitive value is restorative — supporting recovery from neurological injury, reducing chronic neuroinflammation, and stabilising the upstream systems that cognitive function depends on.

Can CJC-1295 with DAC be stacked with other nootropics?

Yes, and it is commonly paired. The cleanest pairings are with compounds on complementary pathways — anxiolytic (selank), neurotrophic (semax), sleep-architecture (DSIP), or anti-inflammatory (LL-37) — rather than with other compounds engaging the same pathway.

Can CJC-1295 with DAC be stacked with other nootropics?

Yes, and it is commonly paired. The cleanest pairings are with compounds on complementary pathways — anxiolytic (selank), neurotrophic (semax), sleep-architecture (DSIP), or anti-inflammatory (LL-37) — rather than with other compounds engaging the same pathway.

Is CJC-1295 with DAC a true nootropic?

Not in the caffeine-or-modafinil sense. CJC-1295 with DAC does not acutely sharpen attention or working memory in healthy users. Its cognitive value is restorative — supporting recovery from neurological injury, reducing chronic neuroinflammation, and stabilising the upstream systems that cognitive function depends on.

What class of compound is CJC-1295 with DAC?

CJC-1295 with DAC is classified as a Long-acting GHRH analogue. Within this class, alternative names and analogues include CJC-1295 DAC, Long-acting GHRH. The class-level pharmacology shapes both the clinical applications and the safety profile; the cognitive / neurological literature treats CJC-1295 with DAC alongside its class peers when evaluating relative merits.

What is the evidence base for CJC-1295 with DAC?

CJC-1295 with DAC's evidence base sits at phase ii human data; widely used off-label. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The cognitive / neurological interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Should I cycle CJC-1295 with DAC?

Standard cycle for CJC-1295 with DAC is 8–12 weeks of 1-2x weekly 1-2 mg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to CJC-1295 with DAC's ~6-8 days (with DAC) half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

How does CJC-1295 with DAC's half-life affect dosing?

CJC-1295 with DAC has a plasma half-life of ~6-8 days (with DAC), which is long enough that single-weekly dosing is operationally viable. The receptor occupancy curve under 1-2x weekly dosing at 1-2 mg per dose explains the typical onset timeline for cognitive and neurological endpoints.

Home/ Compounds/ CJC-1295 with DAC

CJC-1295 with DAC

Neuroprotection

Researchers tracking CJC-1295 with DAC for cognitive and neurological endpoints describe a restorative rather than stimulant phenotype. The compound supports recovery from neurological injury, modulates neuroinflammatory tone, and stabilises monoamine and HPA-axis signalling. Dosing at 1-2 mg 1-2x weekly via subq delivers exposure consistent with the ~6-8 days (with DAC) half-life and the typical 8-12 week cycle pattern used in nootropic-research protocols.

Cognitive / Neurological Applications

Focus & Executive FunctionCognitive RecoveryNeuroprotectionSleep ArchitectureBDNF Support

Key Takeaways

Cognitive lens: CJC-1295 with DAC acts as a modulator with both restorative and modest activating components for cognitive endpoints.
CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects.
Mechanism: Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release.
Neuro dose: 1-2 mg 1-2x weekly via subq; cognitive effects accumulate across 4-8 weeks.
Cognitive stack partners: Semax, Selank, Semax + Selank Blend.

Cognitive / Neurological Mechanism

Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. For cognitive endpoints specifically, this mechanism translates into restorative rather than stimulant effects: reduction of neuroinflammation, support for BDNF and NGF signalling, modulation of monoamine systems, and stabilisation of cerebral perfusion. The three subsections below examine CJC-1295 with DAC's CNS access route, the neurotrophic and inflammatory effects, and the receptor-level pharmacology.

Central nervous system access

CJC-1295 with DAC reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq route(s) and ~6-8 days (with DAC) half-life set the timeline for CNS exposure. Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.

Monoamine and neurotrophic effects

CJC-1295 with DAC's downstream effects on monoamine systems (dopamine, serotonin, occasionally noradrenaline) and on neurotrophic signalling (BDNF, NGF, NT-3) form the molecular substrate of its observed cognitive phenotype. Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. For users tracking cognitive endpoints over the typical 1-2x weekly dosing pattern at 1-2 mg, the changes accumulate across 4–8 weeks rather than emerging acutely. The relevant clinical endpoints are sleep quality, recovery capacity, mood stability, and resilience to cognitive stressors.

Inflammation and neurological recovery

One of the most replicated effects across compounds in CJC-1295 with DAC's class (Long-acting GHRH analogue) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. CJC-1295 with DAC's contribution operates on the same axis at 1-2 mg per dose.

Cognitive / Neurological Applications

BDNF Support

BDNF Support is one of the more-reported subjective benefits of CJC-1295 with DAC across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.

Cognitive Recovery

Where CJC-1295 with DAC is used for cognitive recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.

Gut-Brain Axis

For gut-brain axis, CJC-1295 with DAC is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.

Mood Stabilisation

Mood Stabilisation is one of the more-reported subjective benefits of CJC-1295 with DAC across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1-2 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-2 mg	4–6 weeks initial cycle
Neuroprotection focus	SubQ	1-2 mg	1-2x weekly
Maintenance phase	SubQ	1-2 mg	Ongoing with periodic pauses

Dose timing for CJC-1295 with DAC is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 with DAC stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.

CJC-1295 with DAC + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with CJC-1295 with DAC's mechanism in cognitive / neurological protocols.
CJC-1295 with DAC + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with CJC-1295 with DAC's mechanism in cognitive / neurological protocols.
CJC-1295 with DAC + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with CJC-1295 with DAC's mechanism in cognitive / neurological protocols.
CJC-1295 with DAC + DSIP: Mechanism remains incompletely characterised. Pairs naturally with CJC-1295 with DAC's mechanism in cognitive / neurological protocols.

Safety & Regulatory Status

WADA: Banned (S2 class) FDA: Unapproved Research: Phase II human data; widely used off-label

Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible.

Lens-specific safety considerations for cognitive / neurological use of CJC-1295 with DAC: Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

CJC-1295 sustained release of growth hormone in healthy adults

PMID 16940290

Supporting

Long-acting GHRH analogue mechanism and pharmacokinetics

PMID 16352683

CJC-1295 with DAC vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 with DAC	Long-acting GHRH analogue	~6-8 days (with DAC)	Neuroprotection
Semax	ACTH-derived nootropic heptapeptide	CNS effect hours; plasma minutes	A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent
Selank	Tuftsin-derived heptapeptide anxiolytic	CNS effect lasts hours; plasma short	A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder
DSIP	Neuropeptide (sleep)	~7 min plasma; CNS effects longer	A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience
Pinealon	Khavinson tripeptide (pineal-derived)	Short plasma; durable tissue effects	A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models

Frequently Asked Questions

Is CJC-1295 with DAC appropriate alongside SSRIs or other psychiatric medications?

CJC-1295 with DAC's pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding CJC-1295 with DAC to the regimen.

Best route for cognitive applications — injection or oral?

For most CJC-1295 with DAC cognitive use cases, the route that delivers the compound closest to its target site of action is preferred. Subcutaneous administration provides reliable systemic exposure and is the default route in most cognitive research protocols.

Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

Does CJC-1295 with DAC cross the blood-brain barrier?

Direct BBB passage is variable across peptide compounds and is rarely the dominant mechanism. CJC-1295 with DAC produces CNS effects through some combination of: direct BBB transport (at low efficiency for most peptides), vagal-afferent gut-brain axis signalling, and effects on cerebral vasculature where the barrier is locally compromised. The CNS effects observed in research consistently appear at peripheral doses, supporting the indirect-access framework.

What route should I use for CJC-1295 with DAC?

CJC-1295 with DAC is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

How long until I see results from CJC-1295 with DAC?

Acute effects from CJC-1295 with DAC appear within the first week for downstream physiological adaptation. cognitive and neurological endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Clinical Protocol

Start a CJC-1295 with DAC Protocol

Alukard provides physician-supervised cognitive protocols with GMP-certified CJC-1295 with DAC and GMP-certified compounds and comprehensive neurological assessments.

Get Protocol

Quick Facts

Molecular weight: ~3367 Da
Sequence length: 30 aa
Half-life: ~6-8 days (with DAC)
WADA: Banned (S2 class)
FDA: Unapproved
Research: Phase II human data; widely used off-label

Stack Partners

Semax

Selank

Semax + Selank Blend

DSIP

LL-37

Research Note

All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 with DAC unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised cognitive protocols

Start Your Cognitive / Neurological Protocol for CJC-1295 with DAC

Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised